Core Viewpoint - Hema Medical (03309.HK) announced a share buyback of 320,000 shares for a total cost of HKD 579,000 on November 3, 2025, indicating a strategic move to enhance shareholder value [1] Company Summary - Hema Medical's stock closed at HKD 1.82 on November 3, 2025, remaining unchanged from the previous trading day, with a trading volume of 1.19 million shares and a turnover of HKD 2.1346 million [1] - The company has a market capitalization of HKD 2.26 billion, ranking 15th in the medical services sector [1] Financial Metrics - Return on Equity (ROE) stands at -6.36%, significantly lower than the industry average of 0.02%, ranking 39th out of 60 [1] - The circulating market value in Hong Kong is HKD 22.6 billion, compared to the industry average of HKD 78.25 billion, ranking 15th out of 60 [1] - Revenue is reported at HKD 19.35 billion, below the industry average of HKD 38.32 billion, also ranking 15th out of 60 [1] - Net profit margin is at 5.95%, contrasting sharply with the industry average of -843.36%, ranking 25th out of 60 [1] - Gross profit margin is 31.12%, lower than the industry average of 39.76%, ranking 28th out of 60 [1] - Debt ratio is 29.8%, significantly better than the industry average of 74.15%, ranking 21st out of 60 [1]
希玛医疗(03309.HK)发布公告，于2025年11月3日斥资57.9万港元回购32万股